Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling
- PMID: 24496449
- DOI: 10.1242/jcs.140871
Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling
Abstract
Glypican-3 (GPC3) is a proteoglycan that is bound to the cell surface. It is expressed by most hepatocellular carcinomas (HCCs) but not by normal hepatocytes. GPC3 stimulates HCC growth by promoting canonical Wnt signaling. Because glypicans interact with Wnts, it has been proposed that these proteoglycans stimulate signaling by increasing the amount of Wnt at the cell membrane, thus facilitating the interaction of this growth factor with its signaling receptor, Frizzled. However, in this study, we demonstrate that GPC3 plays a more direct role in the stimulation of Wnt signaling. Specifically, we show that, in addition to interacting with Wnt, GPC3 and Frizzled interact directly through the glycosaminoglycan chains of GPC3, indicating that this glypican stimulates the formation of signaling complexes between Wnt and Frizzled. Consistent with this, we show that the binding of Wnt at the cell membrane triggers the endocytosis of a complex that includes Wnt, Frizzled and GPC3. Additional support for our model is provided by the finding that glypican-6 (GPC6) inhibits canonical Wnt signaling, despite the fact that it binds to Wnt at the cell membrane.
Keywords: Frizzled; Glypican-3; Heparan sulphate; Hepatocellular carcinoma; Proteoglycan; Wnt.
Similar articles
-
Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma.FEBS J. 2013 May;280(10):2471-6. doi: 10.1111/febs.12126. Epub 2013 Jan 31. FEBS J. 2013. PMID: 23305321 Review.
-
Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling.Cancer Res. 2005 Jul 15;65(14):6245-54. doi: 10.1158/0008-5472.CAN-04-4244. Cancer Res. 2005. PMID: 16024626
-
Processing by convertases is not required for glypican-3-induced stimulation of hepatocellular carcinoma growth.J Biol Chem. 2005 Dec 16;280(50):41201-6. doi: 10.1074/jbc.M507004200. Epub 2005 Oct 14. J Biol Chem. 2005. PMID: 16227623
-
Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo.Int J Cancer. 2010 Mar 15;126(6):1291-301. doi: 10.1002/ijc.24941. Int J Cancer. 2010. PMID: 19816934
-
Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more.Adv Anat Pathol. 2009 Mar;16(2):125-9. doi: 10.1097/PAP.0b013e3181992455. Adv Anat Pathol. 2009. PMID: 19550373 Review.
Cited by
-
An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.J Biol Chem. 2016 Nov 18;291(47):24676-24687. doi: 10.1074/jbc.M116.746883. Epub 2016 Oct 7. J Biol Chem. 2016. PMID: 27758865 Free PMC article.
-
Glypicans as Cancer Therapeutic Targets.Trends Cancer. 2018 Nov;4(11):741-754. doi: 10.1016/j.trecan.2018.09.004. Epub 2018 Sep 28. Trends Cancer. 2018. PMID: 30352677 Free PMC article. Review.
-
Glypican 6 is a putative biomarker for metastatic progression of cutaneous melanoma.PLoS One. 2019 Jun 14;14(6):e0218067. doi: 10.1371/journal.pone.0218067. eCollection 2019. PLoS One. 2019. PMID: 31199813 Free PMC article.
-
Structural Features of Glypicans and their Impact on Wnt Signaling in Cancer.Proteoglycan Res. 2025 Apr;3(2):e70029. doi: 10.1002/pgr2.70029. Epub 2025 May 13. Proteoglycan Res. 2025. PMID: 40416340 Free PMC article.
-
Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma.Front Oncol. 2022 Feb 16;12:824208. doi: 10.3389/fonc.2022.824208. eCollection 2022. Front Oncol. 2022. PMID: 35251989 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases